| Symbol | GLUE |
|---|---|
| Name | MONTE ROSA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 645 SUMMER STREET,SUITE 102, BOSTON, Massachusetts, 02210, United States |
| Telephone | +1 617 949-2643 |
| Fax | — |
| — | |
| Website | https://www.monterosatx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001826457 |
| Description | Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the bodys natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates. Additional info from NASDAQ: |
(30% Negative) MONTE ROSA THERAPEUTICS, INC. (GLUE) Reports Q2 2026 Financial Results
Read moreWarmuth Markus 🔴 sold 5.5K shares of Monte Rosa Therapeutics, Inc. (GLUE) at $18.92 Transaction Date: May 01, 2026 | Filing ID: 206344
Read moreMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more📋 Warmuth Markus (Officer) plans to sell 5K shares of Monte Rosa Therapeutics, Inc. (at $18,922.01 each, total $103.4M) Filed: May 01, 2026 | ID: 000046
Read moreNew Form DEFA14A - Monte Rosa Therapeutics, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001193125-26-191451 <b>Size:</b> 4 MB
Read moreNew Form SCHEDULE 13G/A - Monte Rosa Therapeutics, Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001193125-26-170903 <b>Size:</b> 36 KB
Read moreMonte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
Read more📋 EDMUND DUNN (Officer) plans to sell 19K shares of MONTE ROSA THERAPEUTICS, INC. (at $18.50 each, total $346K) Filed: Apr 16, 2026 | ID: 003550
Read moreWarmuth Markus 🔴 sold 8.0K shares of Monte Rosa Therapeutics, Inc. (GLUE) at $17.64 Transaction Date: Apr 14, 2026 | Filing ID: 156981
Read more📋 MARKUS WARMUTH (Officer) plans to sell 8K shares of MONTE ROSA THERAPEUTICS, INC. (at $17.64 each, total $141K) Filed: Apr 14, 2026 | ID: 003455
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07119125 | A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Particip… | Phase1 | Healthy Volunteers | Recruiting | 2025-06-27 | 2026-03-01 | ClinicalTrials.gov |
| NCT06597799 | First-in-human Study of MRT-6160 in Healthy Subjects | Phase1 | Healthy Volunteers | Completed | 2024-08-07 | 2025-04-10 | ClinicalTrials.gov |
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | Phase1 | NSCLC | Active_Not_Recruiting | 2022-10-12 | 2027-11-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06597799 |
| MRT-6160 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06597799 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07119125 |
| MRT-8102 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07119125 |
| Oral MRT-2359 | Other | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT05546268 |
| MRT-8102 | DRUG | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07119125 |
| Placebo | DRUG | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07119125 |
| MRT-6160 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06597799 |
| Oral MRT-2359 | DRUG | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT05546268 |